POS0929 VALUE OF LUNG ULTRASOUND FOR THE DETECTION OF INTERSTITIAL LUNG DISEASE IN PATIENTS WITH RHEUMATOID ARTHRITIS

Background Interstitial lung disease (ILD) is an extra-articular manifestation of rheumatoid arthritis (RA) associated with increased morbidity and mortality. High-resolution computed tomography (HRCT) the gold standard for ILD diagnosis, but it has high cost risk ionizing radiation. Lung Ultrasound (LUS) a non-invasive, low-cost, non-ionizing easily performed diagnostic tool. Objectives To establish value LUS in patients RA, using chest HRCT as standard. Methods A cross-sectional study was at Hospital Italiano de Buenos Aires, Argentina. Consecutive RA (ACR/EULAR-2010 criteria), who had least 12 months previous to inclusion.Demographic, clinical, laboratory therapeutic data were recorded. Each patient underwent simplified examination (14 bilateral intercostal spaces -LIS-), assessment B-lines (BL) pleural irregularities (PI). Additionally, 6MWT on each patient. For diagnosis ILD, gold-standard, taking threshold extension interstitial involvement ≥10%, scored by expert specialist. ROC curves made test ability findings (BL PI), 6 MWT, discriminate ILD. Results total 104 included, 21,8 % 82.7% (95% CI 74.0-89.4) women, median age 57.5 years (IQR 47.3 -67.2) duration 8.7 3.3-15.8). 96.2% 90.5-98.9) seropositive factor (RF) and/or anti-citrullinated protein antibodies (ACPA), DAS28-ESR 3.19 2.6-4.6). Methotrexate been used some point 94.2% 87.9-97.8), 46.2% 36.3-56.2) under bDMARD or tsDMARD treatment inclusion. Patients older time (64 vs 54 years, p=0.002) higher erythrocyte sedimentation rate (ERS) C-reactive (CRP) (48 29 mm/h 5.9 3 g/L than without In LUS, more BL (median 26 vs. 1, p <0.001), (Figure 1) PI 4, <0.001) ILD.The accuracy was: AUC 0.88 - 95% 0.78-0.93 0.82 0.74-0.89 4). The best cut-off detection 8 7 PI.The performance sensitive MWT (Table 1). Conclusion presence showed adequate good negative prognostic value. Table 1. Diagnostic Test Sensitivity Specificity LLR positive Positive Prognostic Value Negative 80,95% 79,52% 3,95 0,24 50 94,30 0,88 (0,78-0,93) Pleural (≥7 ) 75,90% 3,36 0,25 45,95 94,03 0,82 (0,74-0,89) 36,84% 92,31% 4,70 0,68 53,85 85,71 Figure Number B lines according pulmonary measured HRCT. REFERENCES: NIL. Acknowledgements: Disclosure Interests Romina Tanten: None declared, Josefina Marin: Johana Zacariaz: Joaquin Maritano: Martin Fullana: Rodolfo Nicolas Alvarado: Javier Rosa Speakers bureau: Eli Lilly, AbbVie/Abbott, Bristol-Myers Squibb(BMS), Amgen, Novartis, Pfizer.